Öz
Amaç
Tutarsız bulgular ve büyük topluluk kohortlarında yayımlanmış uzunlamasına çalışmaların olmaması dikkate alındığında, bu çalışma multipl sklerozlu bireylerde tedavi yöntemleri (enjekte edilebilir vs. oral tedavi) ile psikiyatrik belirtiler ve yaşam kalitesi arasındaki ilişkiyi değerlendirmeyi amaçlamaktadır.
Yöntem
Bu kesitsel çalışma, McDonald’ın 2017 kriterlerine göre tanı almış çoklu multipl sklerozlu 42 hastayı içeriyordu. Katılımcılar, enjekte edilebilir hastalık modifiye edici tedavi (DMT) alanlar (19 hasta), oral DMT alanlar (22 hasta) ve sağlıklı kontrol grubu (20 hasta) olarak gruplandırılmıştır. Genişletilmiş özürlülük durum ölçeği, Hamilton depresyon değerlendirme ölçeği (HAM-D), sağlık durumu anketi kısa form-36 (SF-36), Hamilton anksiyete değerlendirme ölçeği (HAM-A) ve baş ağrısı etki testi uygulanmıştır.
Bulgular
Sağlıklı kontrol grubuna kıyasla, oral tedavi grubu ve enjekte edilebilir tedavi grubu arasında SF-36 toplam puanları açısından anlamlı düşük bulunmuştur (p<0,05). HAM-D ve HAM-A puanları, sağlıklı kontrol grubunda hem oral tedavi grubundan hem de enjekte edilebilir tedavi grubundan istatistiksel olarak daha düşüktü (p<0,05). HAM-D ve HAM-A puanları, SF-36 toplamı ile negatif olarak korelasyon göstermiştir (p<0,01). Sonuç: Çalışmamız hem oral hem de enjekte edilebilir hastalık modifiye edici tedavi alan hastalarda yaşam kalitesi ve psikiyatrik belirtileri değerlendirerek literatüre katkıda bulunmaktadır. Bulgularımız, oral ve enjekte edilebilir DMT kullanımının yaşam kalitesi ve psikiyatrik belirtiler üzerinde benzer etkilere sahip olduğunu göstermektedir.
Anahtar Kelimeler: Anksiyete, depresyon, enjekte edilebilir tedavi, multipl skleroz, oral tedavi
Kaynakça
Grant WB, Riise T. Multiple sclerosis: A lifestyle disease? Neurology. 2016;86(14):1275-1276.
Ford HL, Gerry E, Johnson MH, Tennant A. Health status and quality of life of people with multiple sclerosis. Disabil Rehabil. 2001;23(12):516-521.
Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6(2):91-98.
Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118(8):622-629.
Kaplan RM, Ganiats TG, Sieber WJ, Anderson JP. The Quality of Well-Being Scale: Critical similarities and differences with SF-36. International Journal for Quality in Health Care. 1998;10(6):509-520.
Rudick RA, Miller DM. Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment. CNS Drugs. 2008;22(10):827-839.
Baumstarck K, Pelletier J, Butzkueven H, Fernández O, Flachenecker P, Idiman E, et al. Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2013;20(6):907-e979.
Baumstarck K, Boyer L, Boucekine M, Michel P, Pelletier J, Auquier P. Measuring the Quality of Life in Patients with Multiple Sclerosis in Clinical Practice: A Necessary Challenge. Mult Scler Int. 2013;2013:1-8.
Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannoni G, Havrdová E, et al. Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. Mult Scler Relat Disord. 2015;4(3):202-218.
Lysandropoulos AP, Havrdova E. “Hidden” factors influencing quality of life in patients with multiple sclerosis. Eur J Neurol. 2015;22(Suppl 2):28-33.
Stuchiner T, Lucas L, Baraban E, Spinelli KJ, Chen C, Smith A, et al. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry. BMC Neurol. 2020;20(1).
Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10(9):507-517.
Jelinek GA, De Livera AM, Marck CH, Brown CR, Neate SL, Taylor KL, et al. Lifestyle, medication and socio-demographic determinants of mental and physical health-related quality of life in people with multiple sclerosis. BMC Neurol. 2016;16(1).
Janzen W, Turpin KVL, Warren SA, Marrie RA, Warren KG. Change in the Health-Related Quality of Life of Multiple Sclerosis Patients over 5 Years. Int J MS Care. 2013;15(1):46-53.
Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221-1231.
Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;2013(5).
Sosyal Güvenlik Kurumu. Erişim Adresi:https://www.sgk.gov.tr/Duyuru/Detay/20231-Donem-Ilac-Geri-Odeme-Komisyonu-Kararlarina-Istinaden-Bedeli-Odenecek-Ilaclar-Listesinde-Yapilan-Duzenlemeler-Hakkinda-Duyuru-2023-08-11-11-36-24
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
Beck AT, Epstei N, Brow G, Steer R. Beck anxiety inventory. J Consult Clin Psychol. 1993.
Hisli N. Beck depresyon envanterinin üniversite öğrencileri için geçerliği, güvenirliği. Psikoloji Dergisi. 1989;7(23):3-13.
Hobart J, Freeman J, Lamping D, Fitzpatrick R, Thompson A. The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosurg Psychiatry. 2001;71(3):363.
McHorney CA, Ware JE, Rachel Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40-66.
Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: The HIT-6TM. Quality of Life Research. 2003;12(8):963-974.
Brola W, Sobolewski P, Fudala M, Flaga S, Jantarski K, Ryglewicz D, et al. Self-reported quality of life in multiple sclerosis patients: preliminary results based on the Polish MS Registry. Patient Prefer Adherence. 2016;10:1647.
Chard D, Trip A, Chataway J. New oral drugs for the treatment of multiple sclerosis. Br J Hosp Med (Lond). 2016;77(9):502-503.
Dolz J, Desrosiers C, Wang L, Yuan J, Shen D, Ben Ayed I. Deep CNN ensembles and suggestive annotations for infant brain MRI segmentation. Comput Med Imaging Graph. 2020;79.
Yahya RN, Kasim AA, Al Gawwam GA. Comparing the Quality of Life among Patients with Relapsing Remitting Multiple Sclerosis in Iraq Using Different Disease Modifying Therapies. Iraqi Journal of Pharmaceutical Sciences. 2018;27(2):102-114.
Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, et al. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial. J Neurol Sci. 2016;365:190-198.
Fox E, Edwards K, Burch G, Wynn DR, Laganke C, Crayton H, et al. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Mult Scler Relat Disord. 2014;3(5):607-619.
Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, et al. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice. Mult Scler Relat Disord. 2018;26:211-218.
Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurol. 2014;14(1).
Chwastiak LA, Ehde DM. Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am. 2007;30(4):803-817.
Janssens ACJW, Van Doorn PA, De Boer JB, Kalkers NF, Van Der Merché FGA, Passchier J, et al. Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler. 2003;9(4):397-403.
Zorzon M, De Masi R, Nasuelli D, Ukmar M, Mucelli RP, Cazzato G, et al. Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol. 2001;248(5):416-421.
